Literature DB >> 9060650

Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model.

T R Kreil1, M M Eibl.   

Abstract

Antibody-dependent enhancement of flavivirus infection, which except for dengue virus is without clear proof in vivo, is still under debate. Recently, postexposure immunoglobulin prophylaxis against tick-borne encephalitis virus, a flavivirus, was claimed to possibly have worsened the outcome of infection due to antibody-dependent enhancement. In the present study, antibody-dependent enhancement and pre- or postexposure protection by passive administration of tick-borne encephalitis virus immunoglobulin were evaluated in a mouse model. Preexposure treatment with homologous murine or heterologous human immunoglobulin provided complete protection against lethal challenge with tick-borne encephalitis virus. For postexposure treatment with antibody, the degree of protection correlated with the amount of immunoglobulin administered and was inversely related to the time interval between infection and treatment. Indications of enhancement of infection would have been increased lethality or reduced mean survival time, but neither was observed under the conditions used in our experiments despite the broad range of immunoglobulin and virus challenge doses applied. In contrast to these in vivo results, antibody-dependent enhancement of tick-borne encephalitis virus infection of murine peritoneal macrophages was readily demonstrable in vitro. Thus, antibody-dependent enhancement of viral infection in vitro does not necessarily predict enhancement in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9060650      PMCID: PMC191419     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  Pathogenesis of neurotropic arbovirus infections.

Authors:  P Albrecht
Journal:  Curr Top Microbiol Immunol       Date:  1968       Impact factor: 4.291

2.  Interaction of tick/borne encephalitis virus with mouse peritoneal macrophages. The effect of antiviral antibody and lectin.

Authors:  J Kopecký; L Grubhoffer; E Tomková
Journal:  Acta Virol       Date:  1991-05       Impact factor: 1.162

Review 3.  [TBE-immunoglobulins--a critical assessment of efficacy].

Authors:  C Aebi; U B Schaad
Journal:  Schweiz Med Wochenschr       Date:  1994-10-22

4.  A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.

Authors:  F X Heinz; R Berger; W Tuma; C Kunz
Journal:  Virology       Date:  1983-04-30       Impact factor: 3.616

5.  Preparation of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation.

Authors:  F X Heinz; C Kunz; H Fauma
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

6.  Immunogenicity and reactogenicity of a highly purified vaccine against tick-borne encephalitis.

Authors:  C Kunz; F X Heinz; H Hofmann
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

7.  Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.

Authors:  J S Peiris; S Gordon; J C Unkeless; J S Porterfield
Journal:  Nature       Date:  1981-01-15       Impact factor: 49.962

Review 8.  Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade.

Authors:  S B Halstead
Journal:  Rev Infect Dis       Date:  1989 May-Jun

9.  The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R Dolin; B S Graham; S B Greenberg; C O Tacket; R B Belshe; K Midthun; M L Clements; G J Gorse; B W Horgan; R L Atmar
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

10.  Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report.

Authors:  R J Phillpotts; J R Stephenson; J S Porterfield
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

View more
  22 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

2.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

3.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 4.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

6.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

Review 7.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

8.  Prime-boost immunization strategies against Chikungunya virus.

Authors:  David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

9.  Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice.

Authors:  Vivian V Costa; Caio T Fagundes; Deborah F Valadão; Thiago V Ávila; Daniel Cisalpino; Rebeca F Rocha; Lucas S Ribeiro; Fernando R Ascenção; Lucas M Kangussu; M Q Celso; Ruiz G Astigarraga; Frederico L Gouveia; Tarcília A Silva; Daniela Bonaventura; Divaldo de Almeida Sampaio; Ana Cristina L Leite; Mauro M Teixeira; Danielle G Souza
Journal:  Med Microbiol Immunol       Date:  2014-04-11       Impact factor: 3.402

Review 10.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.